Patents by Inventor Philippe Michel Rene Bouillot

Philippe Michel Rene Bouillot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOSUPPRESSANT FORMULATIONS
    Publication number: 20220064110
    Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.
    Type: Application
    Filed: April 14, 2021
    Publication date: March 3, 2022
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20220016076
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: June 2, 2020
    Publication date: January 20, 2022
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke
  • IMMUNOSUPPRESSANT FORMULATION
    Publication number: 20210161860
    Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • IMMUNOSUPPRESSANT FORMULATIONS
    Publication number: 20200199069
    Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • IMMUNOSUPPRESSANT FORMULATION
    Publication number: 20190328705
    Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.
    Type: Application
    Filed: March 21, 2019
    Publication date: October 31, 2019
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20190054065
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke
  • IMMUNOSUPPRESSANT FORMULATION
    Publication number: 20180207128
    Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.
    Type: Application
    Filed: March 20, 2018
    Publication date: July 26, 2018
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
    Publication number: 20170027907
    Abstract: The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Inventors: Eric Legangneux, Erik Wallström, Philippe Michel Rene Bouillot, Emeric Reynaud, Frank Dahlke
  • IMMUNOSUPPRESSANT FORMULATION
    Publication number: 20170027906
    Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud
  • IMMUNOSUPPRESSANT FORMULATIONS
    Publication number: 20130273161
    Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 17, 2013
    Inventors: Philippe Michel Rene Bouillot, Emeric Reynaud